ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,733Medicare Part D Prescriptions Filled, Including Refills

Rank: 27 out of 623

$609K Total Retail Price of All Prescriptions

Rank: 24 out of 623

357 Patients Receiving at Least One Drug in Part D
84%Patients 65 Years and Older
32% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Maryland
Lower avg

Schedule Two
Controlled Substances

12% of this provider’s 357 patients filled at least one prescription for a schedule two drug, compared to an average of 6%.

Schedule Three
Controlled Substances

9% of this provider’s 357 patients filled at least one prescription for a schedule three drug, compared to an average of 5%.

Risky Drugs to Seniors

2% of this provider’s 7,475 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$70 was the average price of a prescription from this provider, compared to $66 among peers.

Prescriptions per Patient

24 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Maryland
SIMVASTATIN 345 301 1 2
LISINOPRIL 255 230 2 1
LEVOTHYROXINE SODIUM 227 209 3 4
ATORVASTATIN CALCIUM 209 185 4 10
ATENOLOL 198 164 5 12
FUROSEMIDE 193 183 6 5
METFORMIN HCL ER 176 141 7 56
LISINOPRIL-HYDROCHLOROTHIAZIDE 176 174 7 19
OXYCODONE-ACETAMINOPHEN 173 129 S2 9 42
METOPROLOL SUCCINATE 149 134 10 13
OMEPRAZOLE 140 128 11 7
GLIMEPIRIDE 137 137 12 38
ZOLPIDEM TARTRATE 123 113 13 22
HYDROCHLOROTHIAZIDE 122 109 14 8
METFORMIN HCL 121 104 15 6
LOSARTAN-HYDROCHLOROTHIAZIDE 121 106 15 59
TRAMADOL HCL 120 113 17 15
POTASSIUM CHLORIDE 113 110 18 24
LOSARTAN POTASSIUM 113 101 18 16
TAMSULOSIN HCL 112 97 20 35
CITALOPRAM HBR 110 91 21 21
METOPROLOL TARTRATE 100 92 22 9
AMLODIPINE BESYLATE 98 93 23 3
PRAVASTATIN SODIUM 97 70 24 11
PANTOPRAZOLE SODIUM 88 77 25 26
CARVEDILOL 87 87 26 32
GABAPENTIN 85 68 27 18
PREDNISONE 83 78 28 40
ISOSORBIDE MONONITRATE ER 78 78 29 64
CRESTOR 76 66 30 28
DIGOXIN 76 76 30 63
NEXIUM 75 60 32 43
WARFARIN SODIUM 73 73 33 14
MELOXICAM 72 72 34 50
HYDROCODONE-ACETAMINOPHEN 71 58 S3 35 17
DIOVAN 66 66 36 48
CELEBREX 63 63 37 118
FENOFIBRATE 58 55 38 71
ACTOS 57 45 39 128
AMITRIPTYLINE HCL 56 56 R 40 135
ATENOLOL-CHLORTHALIDONE 55 55 41 152
ALLOPURINOL 53 37 42 44
CYMBALTA 53 38 42 52
AZITHROMYCIN 51 43 44 45
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.